Dalbavancin in Gram-positive periprosthetic joint infections–authors' response.

Drug monitoring may be mandatory for properly managing the duration of the optimal treatment.[5] We agree that the number of previous PJI episodes are a key determinant of treatment outcome and we would like to thank Courjon I et al. i for pointing this out. The treatment duration was based on the treatment algorithm from Li I et al. i with a minimum total treatment of 12 weeks in the standard of care (SoC) and the DAL group.[4] The patients were treated with DAL by two different regimens: a first dose of 1500 mg on day 1 and a second dose of either 1500 mg (regimen-1) or 1000 mg (regimen-2) on day 8. DAL dosage or its combination with other antimicrobial agents and its real-life use for the treatment of Gram-positive prosthetic joint infections (PJIs) is not established.[1] Nevertheless, DAL treatment allows earlier discharge, reducing hospital stay, and seems to be safe, efficient and cost saving.[2],[3] Currently, long-term oral antibiotic treatment is required for the treatment of PJI.[4] However, DAL maybe an attractive alternative. [Extracted from the article]